424
Views
7
CrossRef citations to date
0
Altmetric
Special Report

Novel anti-obesity drugs and plasma lipids

, , , , , & show all
Pages 179-187 | Published online: 18 Jan 2017

References

  • WHO. Obesity and overweight (2013). www.who.int/mediacentre/factsheets/fs311/en/index.html
  • Shamseddeen H, Getty JZ, Hamdallah IN, Ali MR. Epidemiology and economic impact of obesity and Type 2 diabetes. Surg. Clin. North Am. 91(6), 1163–1172, vii (2011).
  • Kyriazis I, Rekleiti M, Saridi M et al. Prevalence of obesity in children aged 6-12 years in Greece: nutritional behaviour and physical activity. Arch. Med. Sci. 9(5), 859–864 (2012).
  • Haslam DW, James WP. Obesity. Lancet 366(9492), 1197–1209 (2005).
  • Aguilera CM, Gil-Campos M, Canete R, Gil A. Alterations in plasma and tissue lipids associated with obesity and metabolic syndrome. Clin. Sci. (Lond.) 114(3), 183–193 (2008). • Interesting review evaluating alterations in plasma and tissue lipids associated with obesity.
  • Li JJ, Wang H, Tino JA et al. 2-hydroxy-Narylbenzenesulfonamides as ATP-citrate lyase inhibitors. Bioorg. Med. Chem. Lett. 17(11), 3208–3211 (2007).
  • Heal DJ, Smith SL, Fisas A, Codony X, Buschmann H. Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders. Pharmacol. Ther. 117(2), 207–231 (2008).
  • Florentin M, Tselepis AD, Elisaf MS, Rizos CV, Mikhailidis DP, Liberopoulos EN. Effect of non-statin lipid lowering and anti-obesity drugs on LDL subfractions in patients with mixed dyslipidaemia. Curr. Vasc. Pharmacol. 8(6), 820–830 (2010).
  • Rizzo M, Mikhailidis DP. There is more to predicting vascular disease than just established risk factors. Curr. Pharm. Des. 17(33), 3608–3610 (2011).
  • Rizzo M, Kotur-Stevuljevic J, Berneis K et al. Atherogenic dyslipidemia and oxidative stress: a new look. Transl. Res. 153(5), 217–223 (2009).
  • Mceneny J, Blair S, Woodside JV, Murray L, Boreham C, Young IS. High-density lipoprotein subfractions display proatherogenic properties in overweight and obese children. Pediatr. Res. 74(3), 279–283 (2013).
  • Otocka-Kmiecik A, Mikhailidis DP, Nicholls SJ, Davidson M, Rysz J, Banach M. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog. Lipid Res. 51(4), 314–324 (2012).
  • Greenberg AS, Obin MS. Obesity and the role of adipose tissue in inflammation and metabolism. Am. J. Clin. Nutr. 83(2), 461S–465S (2006).
  • Bhutani S, Klempel MC, Kroeger CM, Trepanowski JF, Varady KA. Alternate day fasting and endurance exercise combine to reduce body weight and favorably alter plasma lipids in obese humans. Obesity (Silver Spring) 21(7), 1370–1379 (2013).
  • Pattyn N, Cornelissen VA, Eshghi SR, Vanhees L. The effect of exercise on the cardiovascular risk factors constituting the metabolic syndrome: a meta-analysis of controlled trials. Sports Med. 43(2), 121–133 (2013). • Systematic review and meta-analysis evaluating the effect of exercise on cardiovascular risk factors.
  • Jane ML, Ho CC, Chen SC, Huang YC, Lai CH, Liaw YP. A simple method for increasing high-density lipoprotein cholesterol levels: a pilot study of combination aerobic and resistance exercise training. Int. J. Sport Nutr. Exerc. Metab. Accession number: 23307435 (2012) (Epub ahead of print).
  • Fenske W, Parker J, Bloom R. Pharmacotherapy for obesity. Expert Rev. Endocrinol. Metab. 6(4), 563–577 (2011).
  • Muls E, Kolanowski J, Scheen A, Van Gaal L; ObelHyx Study Group. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. Int. J. Obes. Relat. Metab. Disord. 25(11), 1713–1721 (2001).
  • James W, Caterson I, Coutinho W et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N. Engl. J. Med. 363(10), 905–917 (2010).
  • Mikhailidis DP, Elisaf M, Rizzo M et al. “European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr. Vasc. Pharmacol. 9(5), 533–571 (2011).
  • Heal DJ, Gosden J, Smith SL. Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders. Br. J. Clin. Pharmacol. 68(6), 861–874 (2009).
  • Dujovne CA, Zavoral JH, Rowe E, Mendel CM. Silbutramine Study Group. Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia. Am. Heart J. 142(3), 489–497 (2001).
  • Sonnenberg G, Matfin G, Reinhardt R. Drug treatments for obesity: where are we heading and how do we get there? Br. J. Diabet. Vasc. Dis. 7(3), 111–118 (2007).
  • Sjostrom L, Narbro K, Sjostrom CD et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N. Engl. J. Med. 357(8), 741–752 (2007).
  • Le Roux CW, Welbourn R, Werling M et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann. Surg. 246(5), 780–785 (2007).
  • Vincent RP, Le Roux CW. The satiety hormone peptide YY as a regulator of appetite. J. Clin. Pathol. 61(5), 548–552 (2008).
  • Cummings DE, Shannon MH. Roles for ghrelin in the regulation of appetite and body weight. Arch. Surg. 138(4), 389–396 (2003).
  • Stępieę M, Wlazeł RN, Paradowski M et al. Serum concentrations of adiponectin, leptin, resistin, ghrelin and insulin and their association with obesity indices in obese normo- and hypertensive patients – pilot study. Arch. Med. Sci. 8(3), 431–436 (2012).
  • Stepien M, Rosniak-Bak K, Paradowski M et al. Waist circumference, ghrelin and selected adipose tissue-derived adipokines as predictors of insulin resistance in obese patients: preliminary results. Med. Sci. Monit. 17(11), PR13–PR18 (2011).
  • Yang HY, Tae J, Seo YW et al. Novel pyrimidoazepine analogs as serotonin 5-HT(2A) and 5-HT(2C) receptor ligands for the treatment of obesity. Eur. J. Med. Chem. 63, 558–569 (2013).
  • Stevanato J, Bertolla RP, Barradas V, Spaine DM, Cedenho AP, Ortiz V. Semen processing by density gradient centrifugation does not improve sperm apoptotic deoxyribonucleic acid fragmentation rates. Fertil. Steril. 90(3), 889–890 (2008).
  • Blackett P, Tryggestad J, Krishnan S et al. Lipoprotein abnormalities in compound heterozygous lipoprotein lipase deficiency after treatment with a low-fat diet and orlistat. J. Clin. Lipidol. 7(2), 132–139 (2013).
  • Nakou ES, Filippatos TD, Georgoula M et al. The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia. Curr. Med. Res. Opin. 24(7), 1919–1929 (2008).
  • Bryson A, De La Motte S, Dunk C. Reduction of dietary fat absorption by the novel gastrointestinal lipase inhibitor cetilistat in healthy volunteers. Br. J. Clin. Pharmacol. 67(3), 309–315 (2009).
  • US FDA. FDA approves Belviq to treat some overweight or obese adults (2012). www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm309993.htm
  • US FDA. FDA approves weight-management drug Qsymia (2012). www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312468.htm
  • Higgins GA, Sellers EM, Fletcher PJ. From obesity to substance abuse: therapeutic opportunities for 5-HT receptor agonists. Trends Pharmacol. Sci. 34(10), 560–570 (2013).
  • Garfield AS, Heisler LK. Pharmacological targeting of the serotonergic system for the treatment of obesity. J. Physiol. 587(Pt 1), 49–60 (2009).
  • Cone RD. Anatomy and regulation of the central melanocortin system. Nat. Neurosci. 8(5), 571–578 (2005).
  • Higgins GA, Silenieks LB, Lau W et al. Evaluation of chemically diverse 5-HT(2)c receptor agonists on behaviours motivated by food and nicotine and on side effect profiles. Psychopharmacology (Berl.) 226(3), 475–490 (2013).
  • Somerville EM, Horwood JM, Lee MD, Kennett GA, Clifton PG. 5-HT(2C) receptor activation inhibits appetitive and consummatory components of feeding and increases brain c-fos immunoreactivity in mice. Eur. J. Neurosci. 25(10), 3115–3124 (2007).
  • Bai B, Wang Y. The use of lorcaserin in the management of obesity: a critical appraisal. Drug Des. Devel. Ther. 5, 1–7 (2010).
  • Smith BM, Smith JM, Tsai JH et al. Discovery and structureactivity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity. J. Med. Chem. 51(2), 305–313 (2008).
  • Venkatesan A. Arena withdraws lorcaserin diet drug application in Europe. Reuters Health Information (2013).www.medscape.com/viewarticle/803585
  • Martin CK, Redman LM, Zhang J et al. Lorcaserin, a 5-HT(2C) receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure. J. Clin. Endocrinol. Metab. 96(3), 837–845 (2011).
  • Fidler MC, Sanchez M, Raether B et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J. Clin. Endocrinol. Metab. 96(10), 3067–3077 (2011). •• Recent 1-year randomized trial showing the effects of lorcaserin on weight loss in obese and overweight adults.
  • Kennett GA, Clifton PG. New approaches to the pharmacological treatment of obesity: can they break through the efficacy barrier? Pharmacol. Biochem. Behav. 97(1), 63–83 (2010).
  • Katsiki N, Hatzitolios AI, Mikhailidis DP. Naltrexone sustained-release (SR) +bupropion SR combination therapy for the treatment of obesity: ‘a new kid on the block’? Ann. Med. 43(4), 249–258 (2011).
  • Allison DB, Gadde KM, Garvey WT et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring) 20(2), 330–342 (2012). •• Recent randomized controlled trial showing the effects of the phentermine/topiramate combination on weight loss in obese and overweight adults.
  • Gadde KM, Allison DB, Ryan DH et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, Phase 3 trial. Lancet 377(9774), 1341–1352 (2011).
  • Garvey WT, Ryan DH, Look M et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, Phase 3 extension study. Am. J. Clin. Nutr. 95(2), 297–308 (2012).
  • Fleming JW, Mcclendon KS, Riche DM. New obesity agents: lorcaserin and phentermine/topiramate. Ann. Pharmacother. 47(7–8), 1007–1016 (2013).
  • Contrave. Orexigen and FDA identify a clear and feasible path to approval for contrave (2011). www.drugs.com/nda/contrave_110920.html
  • Apovian CM, Aronne L, Rubino D et al. A randomized, Phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring) 21(5), 935–943 (2013). •• Recent randomized trial showing effects of contrave on weight and weight-related risk factors in overweight and obese subjects.
  • Bays HE. Lorcaserin: drug profile and illustrative model of the regulatory challenges of weight-loss drug development. Expert Rev. Cardiovasc. Ther. 9(3), 265–277 (2011).
  • Thatte U. NS-2330 (Neurosearch). Curr. Opin. Investig. Drugs 2(11), 1592–1594 (2001).
  • Axel AM, Mikkelsen JD, Hansen HH. Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat. Neuropsychopharmacology 35(7), 1464–1476 (2010).
  • Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 372(9653), 1906–1913 (2008). •• Randomized, double-blind, placebo-controlled trial reporting promising effects of tesofensine on weight loss in obese subjects.
  • Bray GA, Ryan DH. Drug treatment of the overweight patient. Gastroenterology 132(6), 2239–2252 (2007).
  • Mastinu A, Pira M, Pani L, Pinna GA, Lazzari P. NESS038C6, a novel selective CB1 antagonist agent with anti-obesity activity and improved molecular profile. Behav. Brain Res. 234(2), 192–204 (2012).
  • Mastinu A, Pira M, Pinna GA et al. NESS06SM reduces body weight with an improved profile relative to SR141716A. Pharmacol. Res. 74, 94–108 (2013).
  • Gallwitz B. Anorexigenic effects of GLP-1 and its analogues. Handb. Exp. Pharmacol. 209, 185–207 (2012).
  • Rizzo M, Rizvi AA, Spinas GA, Rini GB, Berneis K. Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors. Expert Opin. Investig. Drugs 18(10), 1495–1503 (2009).
  • Rizzo M, Nikolic D, Banach M et al. The effects of liraglutide on glucose, inflammatory markers and lipoprotein metabolism: current knowledge and future perspectives. Clin. Lipidol. 8, 173–181 (2013).
  • Field BC, Chaudhri OB, Bloom SR. Obesity treatment: novel peripheral targets. Br. J. Clin. Pharmacol. 68(6), 830–843 (2009).
  • Le Stunff H, Coant N, Migrenne S, Magnan C. Targeting lipid sensing in the central nervous system: new therapy against the development of obesity and Type 2 diabetes. Expert Opin. Ther. Targets 17(5), 545–555 (2013).
  • Zinman B, Gerich J, Buse JB et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with Type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 32(7), 1224–1230 (2009).
  • Plutzky J, Garber A, Toft AD, Poulter NR. A meta-analysis demonstrates that liraglutide, a once daily human GLP-1analogue significantly reduces lipids and other markers of cardiovascular risk in Type 2 diabetes Diabetologia 52(Suppl. 1 ), S1–S550 (2009).
  • Rizzo M, Perez-Martinez P, Nikolic D, Montalto G, Lopez-Miranda J. Emerging approaches for the treatment of hypertriglyceridemia. Expert Opin. Pharmacother. 14(14), 1869–1873 (2013).
  • Hata T, Mera Y, Ishii Y et al. JTT-130, a novel intestine-specific inhibitor of microsomal triglyceride transfer protein, suppresses food intake and gastric emptying with the elevation of plasma peptide YY and glucagon-like peptide-1 in a dietary fat-dependent manner. J. Pharmacol. Exp. Ther. 336(3), 850–856 (2011).
  • Swanson HI, Wada T, Xie W et al. Role of nuclear receptors in lipid dysfunction and obesity-related diseases. Drug Metab. Dispos. 41(1), 1–11 (2013).
  • Zhang Y, Huang C. Targeting adipocyte apoptosis: a novel strategy for obesity therapy. Biochem. Biophys. Res. Commun. 417(1), 1–4 (2012).
  • Liew CW, Boucher J, Cheong JK et al. Ablation of TRIP-Br2, a regulator of fat lipolysis, thermogenesis and oxidative metabolism, prevents diet-induced obesity and insulin resistance. Nat. Med. 19(2), 217–226 (2013).
  • Yao Y, Li XB, Zhao W et al. Anti-obesity effect of an isoflavone fatty acid ester on obese mice induced by high fat diet and its potential mechanism. Lipids Health Dis. 9, 49 (2010).
  • Yang L, Chen JH, Lv J et al. Rice protein improves adiposity, body weight and reduces lipids level in rats through modification of triglyceride metabolism. Lipids Health Dis. 11, 24 (2012).
  • Velasquez MT, Bhathena SJ. Role of dietary soy protein in obesity. Int. J. Med. Sci. 4(2), 72–82 (2007).
  • Bhathena SJ, Velasquez MT. Beneficial role of dietary phytoestrogens in obesity and diabetes. Am. J. Clin. Nutr. 76(6), 1191–1201 (2002).
  • Song T, Lee SO, Murphy PA, Hendrich S. Soy protein with or without isoflavones, soy germ and soy germ extract, and daidzein lessen plasma cholesterol levels in golden Syrian hamsters. Exp. Biol. Med. (Maywood) 228(9), 1063–1068 (2003).
  • Setchell KD, Cassidy A. Dietary isoflavones: biological effects and relevance to human health. J. Nutr. 129(3), 758S–767S (1999).
  • Jang EH, Moon JS, Ko JH et al. Novel black soy peptides with antiobesity effects: activation of leptin-like signaling and AMP-activated protein kinase. Int. J. Obes. (Lond.) 32(7), 1161–1170 (2008).
  • Sashidhara KV, Kumar M, Sonkar R, Singh BS, Khanna AK, Bhatia G. Indole-based fibrates as potential hypolipidemic and antiobesity agents. J. Med. Chem. 55(6), 2769–2779 (2012).
  • Cotrim BA, Joglar J, Rojas MJ et al. Unsaturated fatty alcohol derivatives of olive oil phenolic compounds with potential low-density lipoprotein (LDL) antioxidant and antiobesity properties. J. Agric. Food Chem. 60(4), 1067–1074 (2012).
  • Overton HA, Babbs AJ, Doel SM et al. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab. 3(3), 167–175 (2006).
  • Ahn TG, Yang G, Lee HM et al. Molecular mechanisms underlying the anti-obesity potential of prunetin, an O-methylated isoflavone. Biochem. Pharmacol. 85(10), 1525–1533 (2013).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.